Apnimed (NASDAQ:APMD) Raised to Hold at Wall Street Zen

Apnimed (NASDAQ:APMD) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a report released on Saturday.

Apnimed Stock Performance

Apnimed stock opened at $27.00 on Friday. Apnimed has a 52-week low of $16.12 and a 52-week high of $29.15.

Insider Transactions at Apnimed

In other news, major shareholder Morningside Venture Investment purchased 312,500 shares of Apnimed stock in a transaction on Monday, August 3rd. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the transaction, the insider directly owned 7,152,713 shares in the company, valued at approximately $114,443,408. This represents a 4.57% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

About Apnimed

Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.